This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Subramanyan, S. Articles by Kennedy, M. J. Search for Related Content PubMed PubMed Citation Articles by Subramanyan, S. Articles by Kennedy, M. J.

Breast Cancer: High-Dose Therapy

Johns Hopkins Oncology Center, Baltimore, Maryland, USA

Correspondence: Smitha Subramanyan, M.D., Oncology 126, Johns Hopkins Oncology Center, 600 North Wolfe Street, Baltimore, Maryland 21287, USA. Telephone: 410-283-4420; Fax: 410-955-0125; e-mail: ssubrama{at}welchlink.welch.jhu.edu

Breast cancer has become the leading indication for high-dose chemotherapy (HDC) with autologous stem cell rescue (ASCR) in North America. The rapid increase in HDC/ASCR for breast cancer has been driven by belief in the response rates and survival times demonstrated in phase II studies, which have been higher than that of historical controls. However, there is a growing body of data to suggest that selection bias has had a significant impact on the outcome of non-randomized studies of HDC. Few randomized comparisons of HDC to standard-dose chemotherapy exist.

Early studies of dose-intensification and phase II studies of HDC/ASCR for patients with metastatic and high-risk disease are reviewed here, with emphasis on those studies with long-term follow-up. Studies demonstrating the selection bias present in phase II studies of HDC are also discussed. Finally, randomized studies of HDC/ASCR are reviewed, including the National Cancer Institute high-priority trials. Currently, HDC/ASCR for the treatment of breast cancer can only be recommended in the context of a clinical trial. Results of several large randomized trials are awaited to determine the future of HDC/ASCR for breast cancer.

Key Words. Breast neoplasm • Breast diseases • Dose-response relationship • Review • Transplantation, autologous • Bone marrow transplantation • Hematopoietic stem cell transplantation • Transplantation, allogeneic